How Czech Merger Remedies Work (2026 Reform): Clearance, Remedies, Timelines & Monitoring

Merger remedies czech republic practice is entering a period of significant change, and any in-house counsel or M&A adviser weighing a transaction before the Office for the Protection of Competition (ÚOHS) needs to understand what is coming. A 2026 draft amendment to the Czech Competition Act (Act No. 143/2001 Coll. ) has been prepared by ÚOHS and, as reported, would expand the authority’s powers over conditional clearances, adjust negotiation windows and strengthen its monitoring and enforcement tools. This practitioner guide sets out, step by step, when remedies are required, how to draft and negotiate an acceptable commitments package, what documents ÚOHS expects, how long each stage takes, and how monitoring works once clearance is granted.

Read it if you are deciding whether to propose remedies proactively, and how to manage clearance risk under the reformed regime.

For whom: in-house counsel, corporate M&A teams, and external competition and M&A lawyers. Purpose: decide whether to accept or propose remedies, prepare enforceable commitments, and manage timelines and monitoring risk under the proposed 2026 Czech Competition Act reform. Read time: approximately 12 minutes. This guide summarises the current law and publicly reported 2026 draft proposals; it is not legal advice, and transaction-specific questions should be referred to qualified competition counsel. Because the amendment is at draft stage, its final content and timing may change; verify against the enacted text.

Overview, What Are Merger Remedies in the Czech System

Merger remedies are commitments or conditions accepted or imposed to resolve the competition concerns that a concentration would otherwise create. In the Czech Republic, they allow a transaction that would otherwise be prohibited to proceed, subject to structural or behavioural undertakings that remove or neutralise the harm to competition. Rather than blocking a deal outright, ÚOHS can clear it conditionally, provided the parties deliver enforceable, verifiable measures.

Legal Basis (Czech Competition Act and ÚOHS Powers)

The legal framework sits in Act No. 143/2001 Coll. on the Protection of Economic Competition, administered by ÚOHS. The Act empowers the authority to review concentrations that meet the notification thresholds, to prohibit those that would substantially distort competition, and to accept commitments that address identified concerns. ÚOHS may attach conditions and obligations to a clearance decision and monitor their fulfilment. The reported 2026 draft amendment builds on this foundation, clarifying and expanding the authority’s remedy toolbox, a shift that makes early, well-evidenced engagement more valuable than ever for anyone approaching merger remedies czech republic questions.

When Remedies Are Considered

Remedies come into play once ÚOHS forms a preliminary view that a concentration would substantially distort competition on a relevant market, but where a targeted intervention can cure that harm short of prohibition. If the concern cannot be effectively addressed, because the market structure is irreparably damaged, or no credible remedy is available, prohibition remains the outcome. The remedies pathway therefore sits between unconditional clearance and an outright block, and it is where the most intensive negotiation occurs.

Eligibility, When ÚOHS Will Seek Remedies

The trigger for remedies is a finding of material competition concerns. Understanding where these arise helps parties anticipate whether a merger remedies czech republic package will be required and shape their strategy before filing.

Material Competition Concerns That Trigger Remedies

• Horizontal concerns. Where the merging parties are actual or potential competitors and the concentration removes a significant competitive constraint, increasing combined market share and the risk of price rises or reduced output.
• Vertical concerns. Where the merger links suppliers and customers along a supply chain, creating input or customer foreclosure risks that could disadvantage rivals.
• Conglomerate concerns. Where the parties operate in related markets and the combination could allow leveraging, bundling or tying that harms competition, even absent direct overlap.

Market Definition, Evidence Expectations and Provisional Measures

ÚOHS grounds any remedy in a defined relevant product and geographic market. Parties should expect rigorous scrutiny of market shares, closeness of competition, barriers to entry and the counterfactual. Robust economic evidence, internal documents, customer data and, where appropriate, market testing, underpins both the concern and the proposed cure. The 2026 draft amendment is reported to reinforce the authority’s ability to gather evidence and act early.

Step-by-Step: How to Prepare, Propose and Negotiate Merger Remedies Czech Republic

The remedies process runs in parallel with the substantive merger review. Roles shift as the matter progresses: in-house counsel and the transaction team drive commercial decisions, external competition counsel manage the interface with ÚOHS, and a trustee or monitoring officer takes centre stage once a divestiture is agreed. The seven steps below map the full lifecycle from pre-filing assessment to closure of monitoring.

1. Step 1, Pre-filing assessment and remedies audit. Before notification, screen the transaction for overlaps and vertical or conglomerate links. Review internal documents that ÚOHS could request, model likely market definitions, and prepare a mock remedies package identifying which assets or behaviours could be offered. The required result is a clear internal view of clearance risk and a contingency remedy outline. Time estimate: 1–3 weeks.

2. Step 2, Early engagement and market testing. Where risk is material, open early, confidential contacts with ÚOHS. Decide carefully what to disclose, use redacted data where confidentiality is critical, and observe professional confidentiality obligations. Early engagement signals good faith and helps calibrate the authority’s expectations. The required result is an aligned understanding of the concern and the shape of an acceptable remedy. Time estimate: 1–4 weeks.

3. Step 3, Drafting the commitments or remedies offer. Translate the concept into a precise undertaking text. Specify divestiture perimeter, behavioural obligations, KPIs, monitoring metrics and an implementation timetable. Definitions must be watertight and obligations objectively verifiable. The required result is a complete draft commitments document ready to table. Time estimate: 2–6 weeks.

4. Step 4, Negotiation with ÚOHS. Engage in structured negotiation, anticipating that the authority may request additional undertakings or narrow ambiguous language. Where a divestiture is involved, a trustee is typically brought in. Conditional clearance mechanics under the draft amendment may compress this phase. The required result is an agreed remedy package the authority is prepared to accept. Time estimate: 2–12 weeks, depending on complexity.

5. Step 5, Formal decision and conditional clearance. Review the draft decision, resolve any ancillary obligations, and separate publicly disclosable content from confidential annexes. The clearance is granted subject to the agreed conditions and obligations. The required result is a conditional clearance decision. Time estimate: the administrative decision phase under the statutory timelines described below.

6. Step 6, Implementation and monitoring. Execute the divestiture or behavioural obligations under trustee or monitoring officer supervision. Establish the reporting cadence, track KPIs, maintain communications with ÚOHS and manage breach and enforcement risk. The required result is verified compliance with all commitments. Time estimate: a monitoring period commonly running from six months to several years, depending on the remedy.

7. Step 7, Exit and termination of monitoring. Once obligations are fully discharged and the competitive concern durably resolved, ÚOHS closes the monitoring. Counsel and the trustee confirm criteria are met and obtain formal release. The required result is termination of monitoring and release from ongoing obligations. Time estimate: at completion of the monitoring period.

Sample Drafting Guidance for Step 3 (Template Language)

The illustrative clause fragments below are for guidance only and must be reviewed and adapted by qualified counsel before use:

• Divestiture obligation. “The Parties shall divest the Divestment Business as a going concern to a Purchaser approved by the Office within [X] months of the Decision, comprising the assets, intellectual property, personnel and customer contracts listed in Schedule [1].”
• Hold-separate measure. “Pending completion of the divestiture, the Divestment Business shall be held separate, managed independently by a Hold-Separate Manager, and preserved in its current competitive state.”
• Behavioural KPI. “The Parties shall grant non-discriminatory access to [input] on terms no less favourable than those set out in Annex [2], reporting compliance quarterly against the metrics specified therein.”

Step / Who / Duration Timeline Table

Types of Remedies (Divestiture, Behavioural and Hybrid)

ÚOHS, like the European Commission under the EU Merger Regulation, distinguishes between structural and behavioural remedies, and frequently accepts hybrid packages combining both. The choice turns on effectiveness, verifiability and enforceability.

• Structural (divestiture) remedies. The sale of a business, asset package or shareholding to a suitable purchaser. These are generally preferred because they restore competition permanently and require limited ongoing monitoring once complete. A divestiture in a Czech merger must define the perimeter precisely and identify a purchaser capable of running the business as an effective competitor.
• Behavioural remedies. Ongoing commitments regulating conduct, access obligations, non-discrimination undertakings, firewalls or supply commitments. Behavioural remedies in the Czech context require detailed KPIs and sustained monitoring, and are more demanding to enforce than structural cures.
• Hold-separate and interim measures. Provisions preserving a business pending divestiture, often supported by a hold-separate manager, so that competitive value is not eroded during the transition.
• Hybrid packages. Combinations tailored to a specific concern, for example, a partial divestiture accompanied by access commitments where a clean structural fix is not feasible.

Across all forms, the recurring theme in ÚOHS remedies practice is that the authority favours measures it can verify and enforce, backed by a credible trustee mandate.

Required Documents for a Remedies Package

A complete, well-organised submission accelerates review and signals to ÚOHS that the parties can deliver. The authority expects a coherent package linking the identified concern to the proposed cure, supported by evidence of the parties’ ability to implement.

What ÚOHS Expects in a Remedies Package

Timeline and Deadlines: How the 2026 Reform Changes Merger Remedies Czech Republic Practice

Timing is where the proposed 2026 reform bites hardest. Understanding the statutory review structure, and how the draft amendment may recalibrate it, is essential to sequencing a remedies strategy that keeps the deal on track.

Statutory Review Periods and Draft Amendment Changes

Under the current framework, ÚOHS reviews concentrations across defined administrative phases, an initial phase for straightforward cases, followed where necessary by an in-depth phase for cases raising serious concerns. Remedies are typically negotiated within the in-depth phase, and the statutory clock governs how long the authority has to decide. The 2026 draft amendment is reported to recalibrate decision deadlines and encourage earlier use of commitments, which could compress the negotiation runway. Practitioners should treat the current periods as the baseline and monitor the official ÚOHS and legislative portals for the enacted text, as the specific statutory periods may change.

Practical Negotiation Timelines and Tips to Accelerate Clearance

• Front-load the analysis. Complete the remedies audit before filing so a package can be tabled at the first sign of concern.
• Run parallel workstreams. Progress purchaser vetting, trustee selection and asset schedules simultaneously rather than sequentially.
• Use binding, dated milestones. Offer clear implementation deadlines that give ÚOHS confidence the remedy will be delivered.
• Pre-identify a purchaser. Where a divestiture is likely, having a credible buyer ready can materially shorten the merger review timeline at ÚOHS.

Current vs Proposed 2026 Rules

Costs and Fees

Budgeting realistically is part of a sound remedies strategy. Costs span advisory fees, economic evidence, trustee supervision and, for divestitures, substantial implementation expenditure. The ranges below are indicative estimates only and vary significantly with complexity, sector and the number of jurisdictions involved.

Typical Cost Drivers

All figures are indicative and should be confirmed against current ÚOHS schedules and specific engagement terms.

What Changes in 2026

The reported 2026 draft amendment is an important development for anyone advising on merger remedies czech republic matters. As publicly described, it would reshape how ÚOHS engages with commitments and how it polices them afterwards. Because it remains a draft, the details below should be verified against the enacted legislation.

Summary of the 2026 Draft Amendment

The draft is reported to focus on three levers: the authority’s power to impose and shape conditional clearances, the timelines within which commitments must be discussed and decided, and ÚOHS’s monitoring and enforcement reach. Taken together, these changes are expected to make conditional clearance a more central feature of Czech merger control, while raising the bar on how enforceable and measurable commitments must be. The exact statutory wording should be verified against the official text once enacted.

Practical Implications for Parties

• Earlier negotiation pressure. Tighter windows would mean parties must arrive with a workable remedy sooner, leaving little room for a late pivot.
• Greater emphasis on enforceable KPIs. Behavioural remedies will need sharper metrics and clearer reporting to survive scrutiny.
• Wider use of conditional clearances. Commentators expect ÚOHS to deploy conditional clearance more frequently, changing the calculus for deals that previously might have proceeded unconditionally or faced prohibition.

How to Prepare: Negotiation Playbook Adjustments

• Compress your internal timetable. Anticipate shorter windows by completing the remedies audit and economic analysis before filing.
• Line up contingency divestiture buyers. A ready, credible purchaser removes a major source of delay.
• Accelerate trustee appointment. Identify and mandate a trustee early so monitoring can begin without friction.
• Build monitoring infrastructure upfront. Prepare reporting templates and KPI dashboards before clearance, not after.

Common Pitfalls and How to Avoid Them

Most remedies problems are avoidable. They stem from imprecise drafting, weak governance of the monitoring phase, and underestimating the practical burden of implementation.

Typical Errors

• Vague KPIs. Metrics that cannot be objectively measured invite disputes and are likely to be rejected by ÚOHS.
• Weak trustee mandates. A trustee without adequate powers cannot police compliance, undermining the whole remedy.
• Late purchaser vetting. Introducing a divestiture buyer too late risks the authority rejecting it and derailing the timeline.
• Underestimating implementation costs. Carve-outs, data migration and staff transfers routinely cost more than parties expect.
• Inadequate reporting templates. Ad hoc reporting breeds gaps that expose parties to enforcement risk.

Remedies Drafting Checklist

• Define the divestiture perimeter and all key terms precisely.
• Attach measurable, objectively verifiable KPIs to every behavioural obligation.
• Grant the trustee clear powers and reporting lines.
• Include dated implementation milestones and a fallback if deadlines slip.
• Prepare a public summary alongside confidential annexes.
• Secure board resolutions and legal opinions confirming enforceability.

Conclusion and Next Steps

Merger remedies czech republic strategy may be reshaped by the reported 2026 draft amendment, which is expected to push negotiation earlier, raise the bar on enforceable commitments, and expand ÚOHS’s monitoring and sanctioning powers. The parties who fare best will complete their remedies audit before filing, arrive with a precise and verifiable package, line up a credible divestiture purchaser and trustee in advance, and build monitoring infrastructure from the outset. Treat the durations and figures in this guide as typical ranges rather than guarantees, and verify all statutory changes against the enacted text. For transaction-specific drafting, negotiation and monitoring advice tailored to your deal, seek qualified Czech competition counsel before you file.

Sources

1. Office for the Protection of Competition (ÚOHS)
2. Council Regulation (EC) No 139/2004 (EU Merger Regulation), EUR-Lex
3. European Commission, Mergers
4. Act No. 143/2001 Coll., on the Protection of Economic Competition
5. OECD, Competition
6. Czech Bar Association (Česká advokátní komora)
7. Supreme Administrative Court of the Czech Republic